Engineered Tissue for Type 1 Diabetes
Type 1 Diabetes
Pre-clinicalActive
Key Facts
About Fluicell
Fluicell is pioneering a new paradigm in tissue engineering with its proprietary Nexocyte™ platform, which leverages twenty years of R&D and its Biopixlar bioprinting technology to create functional tissues with single-cell precision. The company is advancing a pipeline focused on tissue-based therapeutics for type 1 diabetes and complex in vitro models for cardiac toxicity and kidney disease screening. By enabling the design and production of tailored biological tissues, Fluicell aims to transform the treatment of chronic diseases and accelerate drug development for its pharmaceutical partners.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |